|
A phase 1b study of crizotinib in combination with temsirolimus in pediatric ALK- or MET-aberrated relapsed or refractory neuroblastoma (ITCC-053): Results of the phase 1 part. |
|
|
Research Funding - Pfizer (Inst); Takeda (Inst) |
|
|
Research Funding - Takeda (Inst) |
|
Natasha K.A. van Eijkelenburg |
Speakers' Bureau - EUSA Pharma |
|
|
Research Funding - Merus NV (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst) |
|
|
Consulting or Advisory Role - AstraZeneca; Bayer; BMS; Pfizer; Servier |
|
|
Consulting or Advisory Role - Janssen; Jazz Pharmaceuticals; Novartis |
Research Funding - Bluebird Bio (Inst); Jazz Pharmaceuticals (Inst); Novartis (Inst); Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - Medac (Inst) |
|
|
Honoraria - Bayer; Eisai; Merck |
Consulting or Advisory Role - Illumina |
|
|
Consulting or Advisory Role - AstraZeneca |
Travel, Accommodations, Expenses - Jazz Pharmaceuticals |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
Pauline L.H. Winkler-Seinstra |
Research Funding - Jazz Pharmaceuticals (Inst); Pfizer (Inst) |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
Consulting or Advisory Role - Abbvie (Inst); Incyte (Inst); Jazz Pharmaceuticals (Inst); Kura Oncology (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst) |
Research Funding - Abbvie/Genentech (Inst); Daiichi Sankyo (Inst); Jazz Pharmaceuticals (Inst); Kura Oncology (Inst); Pfizer (Inst); Takeda (Inst) |
|
|
No Relationships to Disclose |